WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
TCRX
TSCAN THERAPEUTICS INC
$397.42M$21.05M-$80.10M-$89.22M-$1.3655.52%N/AN/AN/A2024-05-07
LSTA
LISATA THERAPEUTICS INC
$27.08M$0.00-$22.98M-$20.84M-$2.58N/AN/AN/AN/A2024-05-07
FDMT
4D MOLECULAR THERAPEUTICS INC
$1.79B$20.72M-$95.09M-$100.84M-$2.58562.29%7.96%N/AN/A2024-05-08
MRNS
MARINUS PHARMACEUTICALS INC
$483.59M$30.99M-$125.31M-$141.41M-$2.6321.63%N/AN/AN/A2024-05-09
CVAC
CUREVAC NV
$682.84M$45.62M-$294.67M-$321.59M-$1.56-52.95%N/AN/AN/A2024-05-21
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
$419.32M$170.28M-$182.30M-$225.25M-$1.56-8.11%25.06%N/AN/A2024-05-01
ADAG
ADAGENE INC
$110.29M$22.67MN/A-$36.44M-$0.8677.91%N/AN/AN/A2024-03-28
MNKD
MANNKIND CORP
$1.25B$198.96M$20.62M-$11.94M-$0.0499.42%48.17%N/AN/A2024-05-07
RXRX
RECURSION PHARMACEUTICALS INC
$2.39B$44.58M-$299.66M-$328.07M-$1.5811.88%N/AN/AN/A2024-05-06
FOLD
AMICUS THERAPEUTICS INC
$3.50B$399.36M-$92.08M-$151.58M-$0.5121.30%34.35%N/AN/A2024-05-08
TSHA
TAYSHA GENE THERAPIES INC
$592.85M$15.45M-$104.02M-$111.57M-$0.96517.55%N/AN/AN/A2024-05-09
CASI
CASI PHARMACEUTICALS INC
$40.13M$42.26MN/A-$40.42M-$3.0114.21%N/AN/AN/A2024-04-24
APLS
APELLIS PHARMACEUTICALS INC
$7.05B$396.59M-$495.21M-$528.63M-$4.45425.83%N/AN/AN/A2024-05-02
PULM
PULMATRIX INC
$5.92M$6.80M-$14.60M-$16.25M-$4.4341.19%113.61%N/AN/A2024-03-28
URGN
UROGEN PHARMA LTD
$510.47M$82.71M-$81.90M-$102.24M-$3.5528.52%136.08%N/AN/A2024-05-09
CLLS
CELLECTIS SA
$148.41M$24.41M-$27.35M-$85.01M-$1.65N/A-0.84%N/AN/A2024-05-08
ALEC
ALECTOR INC
$582.16M$97.06M-$116.33M-$130.39M-$1.56-27.36%28.52%N/AN/A2024-05-02
IPHA
INNATE PHARMA SA
$191.63M$67.00M-$700.00k-$8.23M-$0.1011.63%-8.70%N/AN/A2024-05-14
BRTX
BIORESTORATIVE THERAPIES INC
$6.56M$130.20k-$15.92M-$15.94M-$4.127.51%1.64%N/AN/A2024-05-12
HOOK
HOOKIPA PHARMA INC
$71.24M$20.13M-$77.34M-$81.58M-$0.8641.27%21.41%N/AN/A2024-05-09
IMRN
IMMURON LTD
$15.83M$2.34MN/A-$2.54M-$0.44224.30%12.68%N/AN/A
BLRX
BIOLINERX LTD
$80.81M$4.80M-$57.06M-$60.61M-$0.06N/AN/AN/AN/A2024-05-22
RPTX
REPARE THERAPEUTICS INC
$196.99M$51.13M-$99.03M-$93.80M-$2.23-61.21%N/AN/AN/A2024-05-07
TNXP
TONIX PHARMACEUTICALS HOLDING CORP
$7.80M$3.99M-$117.15M-$123.42M-$9.07N/AN/AN/AN/A2024-05-06
CRVO
CERVOMED INC
$111.33M$1.53M-$8.13M-$8.13M-$6.84N/AN/AN/AN/A2024-05-13
IMNN
IMUNON INC
$13.16M$125.00k-$28.28M-$27.86M-$3.27-75.00%-24.21%N/AN/A2024-03-28
PSTX
POSEIDA THERAPEUTICS INC
$297.19M$64.70M-$109.04M-$123.43M-$1.37-50.42%N/AN/AN/A2024-05-07
AADI
AADI BIOSCIENCE INC
$58.19M$24.35M-$64.90M-$65.77M-$2.4460.06%3.85%N/AN/A2024-05-08
STOK
STOKE THERAPEUTICS INC
$656.12M$8.78M-$109.88M-$104.70M-$2.38-29.22%N/AN/AN/A2024-05-02
OVID
OVID THERAPEUTICS INC
$215.67M$391.70k-$50.74M-$52.34M-$0.74-73.93%N/AN/AN/A2024-05-03
SILO
SILO PHARMA INC
$5.43M$72.10k-$3.70M-$3.70M-$1.200.00%N/AN/AN/A
MRVI
MARAVAI LIFESCIENCES HOLDINGS INC
$2.16B$288.95M$731.76M-$119.03M-$0.90-67.28%18.47%N/AN/A2024-05-06
LPTX
LEAP THERAPEUTICS INC
$71.17M$0.00-$81.40M-$81.41M-$3.98N/AN/AN/AN/A2024-05-13
BRNS
BARINTHUS BIOTHERAPEUTICS PLC
$90.69M$802.00k-$69.64M-$73.35M-$1.91-98.21%N/AN/AN/A2024-05-10
LTRN
LANTERN PHARMA INC
$105.05M$0.00-$15.79M-$15.96M-$1.47N/AN/AN/AN/A2024-05-07
STRO
SUTRO BIOPHARMA INC
$307.84M$153.73M-$66.98M-$106.79M-$1.78126.84%31.96%N/AN/A2024-03-28
VXRT
VAXART INC
$224.28M$7.38M-$73.58M-$82.47M-$0.576,796.26%12.15%N/AN/A2024-05-02
CRMD
CORMEDIX INC
$228.72M$0.00-$46.23M-$46.34M-$0.91-100.00%-100.00%N/AN/A2024-05-13
CVKD
CADRENAL THERAPEUTICS INC
$10.25M$0.00-$8.34M-$8.36M-$0.62N/AN/AN/AN/A
PASG
PASSAGE BIO INC
$72.83M$0.00-$98.34M-$102.06M-$1.86N/AN/AN/AN/A2024-05-09
KURA
KURA ONCOLOGY INC
$1.61B$0.00-$150.23M-$152.63M-$2.08N/AN/AN/AN/A2024-05-08
ORIC
ORIC PHARMACEUTICALS INC
$907.22M$0.00-$99.67M-$100.70M-$1.96N/AN/AN/AN/A2024-05-06
LGND
LIGAND PHARMACEUTICALS INC
$1.26BN/AN/AN/AN/AN/AN/AN/AN/A2024-05-02
BCAB
BIOATLA INC
$166.41M$0.00-$122.24M-$123.46M-$2.58N/A-100.00%N/AN/A2024-05-09
IPSC
CENTURY THERAPEUTICS INC
$276.77M$2.24M-$122.40M-$136.67M-$2.30-57.01%N/AN/AN/A2024-05-13
NXTC
NEXTCURE INC
$53.99M$0.00-$58.47M-$62.72M-$2.25N/AN/AN/AN/A2024-05-02
VRCA
VERRICA PHARMACEUTICALS INC
$239.66M$5.12M-$62.20M-$67.00M-$1.48-43.27%N/AN/AN/A2024-05-07
CALC
CALCIMEDICA INC
$23.82M$0.00-$37.58M-$37.61M-$30.12N/AN/AN/AN/A2024-05-13
XENE
XENON PHARMACEUTICALS INC
$3.24B$0.00-$179.14M-$182.39M-$2.73-100.00%N/AN/AN/A2024-05-07
KRRO
KORRO BIO INC
$710.18M$0.00-$73.91M-$81.17M-$53.08N/AN/AN/AN/A2024-05-10
LVTX
LAVA THERAPEUTICS NV
$102.79M$7.36M-$47.16M-$45.62M-$1.71-63.54%N/AN/AN/A2024-04-09
KYMR
KYMERA THERAPEUTICS INC
$2.45B$78.59M-$143.20M-$146.96M-$2.5267.84%N/AN/AN/A2024-05-02
ABEO
ABEONA THERAPEUTICS INC
$200.79M$3.50M-$50.57M-$54.19M-$2.53147.52%3.14%N/AN/A2024-05-09
AVIR
ATEA PHARMACEUTICALS INC
$336.66M$0.00-$134.52M-$135.96M-$1.63N/AN/AN/AN/A2024-05-06
XBIT
XBIOTECH INC
$243.30M$0.00-$22.57M-$24.56M-$0.81-100.00%N/AN/AN/A2024-05-08
CLSD
CLEARSIDE BIOMEDICAL INC
$124.78M$8.23M-$32.42M-$32.49M-$0.53519.89%207.34%N/AN/A2024-05-09
ZNTL
ZENTALIS PHARMACEUTICALS INC
$1.08B$0.00-$291.40M-$292.19M-$4.47N/A-100.00%N/AN/A2024-05-08
GLTO
GALECTO INC
$21.15M$0.00-$37.52M-$38.35M-$1.44N/AN/AN/AN/A2024-04-26
KRON
KRONOS BIO INC
$74.52M$6.29M-$107.76M-$112.67M-$1.95N/AN/AN/AN/A2024-05-08
VRAX
VIRAX BIOLABS GROUP LTD
$1.28M$79.30kN/A-$6.92M-$2.941,276.75%N/AN/AN/A
BDTX
BLACK DIAMOND THERAPEUTICS INC
$253.42M$0.00-$82.01M-$82.44M-$1.88N/AN/AN/AN/A2024-05-07
CGEM
CULLINAN ONCOLOGY INC
$763.55M$0.00-$166.97M-$153.16M-$3.69N/AN/AN/AN/A2024-05-09
PCVX
VAXCYTE INC
$7.43B$0.00-$392.10M-$402.27M-$4.14N/AN/AN/AN/A2024-05-06
ARTL
ARTELO BIOSCIENCES INC
$4.74M$0.00-$9.25M-$9.29M-$3.14N/AN/AN/AN/A2024-05-09
ANNX
ANNEXON INC
$703.10M$0.00-$130.97M-$134.24M-$1.77N/AN/AN/AN/A2024-05-06
NKTX
NKARTA INC
$547.78M$0.00-$109.41M-$117.50M-$2.40N/A-100.00%N/AN/A2024-05-09
PRLD
PRELUDE THERAPEUTICS INC
$261.97M$0.00-$118.73M-$121.83M-$2.02N/AN/AN/AN/A2024-05-06
NAUT
NAUTILUS BIOTECHNOLOGY INC
$346.52M$0.00-$57.97M-$63.68M-$0.51N/AN/AN/AN/A2024-05-01
ADMA
ADMA BIOLOGICS INC
$1.54B$258.22M$5.12M-$28.24M-$0.1367.59%72.34%N/AN/A2024-05-08
CGON
CG ONCOLOGY INC
$2.73B$204.00k-$55.48M-$67.80M-$15.656.81%N/AN/AN/A
PPBT
PURPLE BIOTECH LTD
$12.12M$0.00$22.27M$19.88MN/AN/A-100.00%N/AN/A2024-05-09
SNDX
SYNDAX PHARMACEUTICALS INC
$1.96B$0.00-$208.40M-$209.36M-$2.98N/A-100.00%N/AN/A2024-05-06
CBUS
CIBUS INC
$525.35M$1.82M-$244.57M-$267.63M-$25.951,057.32%50.41%N/AN/A2024-04-29
PMVP
PMV PHARMACEUTICALS INC
$84.88M$0.00-$68.07M-$68.96M-$1.44N/AN/AN/AN/A2024-05-08
ACST
ACASTI PHARMA INC
$31.96M$0.00-$48.89M-$38.77M-$5.08N/AN/AN/AN/A
BNTC
BENITEC BIOPHARMA INC
$13.30M$61.00k-$21.44M-$21.81M-$0.11-1.61%N/AN/AN/A2024-05-13
EXAI
EXSCIENTIA PLC
$726.56M$25.74M-$192.47M-$187.13M-$1.51-22.51%N/AN/AN/A2024-05-20
BCRX
BIOCRYST PHARMACEUTICALS INC
$1.06B$331.41M-$116.34M-$226.54M-$1.1822.37%74.21%N/AN/A2024-05-01
AURA
AURA BIOSCIENCES INC
$381.18M$0.00-$73.14M-$76.41M-$1.93N/AN/AN/AN/A2024-05-06
CMPX
COMPASS THERAPEUTICS INC
$282.06M$0.00-$40.60M-$42.49M-$0.33N/AN/AN/AN/A2024-05-06
DSGN
DESIGN THERAPEUTICS INC
$220.89M$0.00-$66.29M-$66.86M-$1.19N/AN/AN/AN/A2024-05-07
PTIX
PROTAGENIC THERAPEUTICS INC
$8.07M$0.00-$3.80M-$3.93M-$0.91N/AN/AN/AN/A2024-05-15
ABOS
ACUMEN PHARMACEUTICALS INC
$246.33M$0.00-$51.61M-$52.37M-$1.08N/AN/AN/AN/A2024-05-06
CELC
CELCUITY INC
$553.03M$0.00-$58.31M-$63.78M-$2.69N/AN/AN/AN/A2024-05-13
ALDX
ALDEYRA THERAPEUTICS INC
$181.40M$0.00-$35.21M-$37.54M-$0.64N/AN/AN/AN/A2024-05-02
MREO
MEREO BIOPHARMA GROUP PLC
$420.77M$10.00M-$27.34M-$29.47M-$0.20N/AN/AN/AN/A2024-03-29
SLNO
SOLENO THERAPEUTICS INC
$1.39B$0.00-$36.71M-$38.99M-$2.36N/AN/AN/AN/A2024-05-07
GPCR
STRUCTURE THERAPEUTICS INC
$2.00B$0.00-$88.46M-$89.62M-$2.43N/AN/AN/AN/A2024-03-28
AIM
AIM IMMUNOTECH INC
$21.64M$193.00k-$20.27M-$20.78M-$0.4344.03%1.75%N/AN/A2024-03-29
EPIX
ESSA PHARMA INC
$378.68M$0.00-$25.69M-$25.80M-$0.59N/AN/AN/AN/A2024-05-07
GLMD
GALMED PHARMACEUTICALS LTD
$1.32M$0.00-$7.76M-$7.54M-$3.78N/A-100.00%N/AN/A
MACK
MERRIMACK PHARMACEUTICALS INC
$214.11M$0.00-$1.17M-$1.18M-$0.08N/AN/AN/AN/A2024-05-02
SYRS
SYROS PHARMACEUTICALS INC
$154.49M$9.94M-$157.12M-$164.57M-$5.81-33.23%37.12%N/AN/A2024-05-08
VOR
VOR BIOPHARMA INC
$150.65M$0.00-$109.64M-$117.86M-$1.75N/AN/AN/AN/A2024-05-09
THRD
THIRD HARMONIC BIO INC
$385.57M$0.00-$30.23M-$30.82M-$0.78N/AN/AN/AN/A2024-05-09
ERAS
ERASCA INC
$312.08M$0.00-$121.31M-$125.04M-$0.83N/AN/AN/AN/A2024-05-09
MNOV
MEDICINOVA INC
$72.10M$1.00M-$8.35M-$8.57M-$0.17N/AN/AN/AN/A2024-05-09
ALRN
AILERON THERAPEUTICS INC
$31.47M$0.00-$12.83M-$12.94M-$2.86N/AN/AN/AN/A2024-05-06
NUVB
NUVATION BIO INC
$869.61M$0.00-$75.65M-$75.80M-$0.35N/AN/AN/AN/A2024-05-02
TYRA
TYRA BIOSCIENCES INC
$856.09M$0.00-$68.78M-$69.13M-$1.62N/AN/AN/AN/A2024-05-02

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Mar 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -19.33% over the past year, underperforming other biotech stocks by -14 percentage points.

Incyte has an average 1 year price target of $73.92, an upside of 29.41% from Incyte's current stock price of $57.12.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Incyte, 25% have issued a Strong Buy rating, 16.67% have issued a Buy, 58.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 22 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -19.23% over the past year, underperforming other biotech stocks by -13 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $38.00, an upside of 13.37% from Harmony Biosciences Holdings's current stock price of $33.52.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Harmony Biosciences Holdings, 42.86% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 14.29% have issued a Sell rating, and 14.29% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock return 31.68% over the past year, overperforming other biotech stocks by 37 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 114.44% from Voyager Therapeutics's current stock price of $9.56.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 11.87%.

Carisma Therapeutics's dividend payout ratio of -9.6% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 44.64%, which is 33 percentage points higher than the biotech industry average of 11.87%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.31%, which is -11 percentage points lower than the biotech industry average of 11.87%.

Royalty Pharma's dividend payout ratio of 23.6% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.47% in the last day, and up 0.83% over the last week. Ibio was the among the top gainers in the biotechnology industry, gaining 192.17% yesterday.

IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 31.68% in the past year. It has overperformed other stocks in the biotech industry by 37 percentage points.

2. Bionomics Limited (NASDAQ:BNOX)


Bionomics Limited (NASDAQ:BNOX) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Bionomics Limited has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Bionomics Limited's stock has dropped -54.02% in the past year. It has underperformed other stocks in the biotech industry by -48 percentage points.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -18.56% in the past year. It has underperformed other stocks in the biotech industry by -13 percentage points.

Are biotech stocks a good buy now?

47.55% of biotech stocks rated by analysts are a buy right now. On average, analysts expect biotech stocks to rise by 66.01% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 14.3x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.